The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
TNF neutralization in MS: Results of a randomized, placebo-controlled multicenter study
Abstract
Objective: A double-blind, placebo-controlled phase II study was conducted in 168 patients, most with relapsing-remitting MS, to evaluate whether lenercept would reduce new lesions on MRI. Background: Tumor necrosis factor (TNF) has been implicated in MS pathogenesis, has been identified in active MS lesions, is toxic to oligodendrocytes in vitro, and worsens the severity of experimental allergic encephalomyelitis (EAE) in animals. Lenercept, a recombinant TNF receptor p55 immunoglobulin fusion protein (sTNFR-IgG p55), protects against EAE. Methods: Patients received 10, 50, or 100 mg of lenercept or placebo IV every 4 weeks for up to 48 weeks. MRI scans and clinical evaluations were performed at screening, at baseline, and then every 4 weeks (immediately before dosing) through study week 24. Results: There were no significant differences between groups on any MRI study measure, but the number of lenercept-treated patients experiencing exacerbations was significantly increased compared with patients receiving placebo (p = 0.007) and their exacerbations occurred earlier (p = 0.006). Neurologic deficits tended to be more severe in the lenercept treatment groups, although this did not affect Expanded Disability Status Scale scores. Anti-lenercept antibodies were present in a substantial number of treated patients; serum lenercept trough concentrations were detectable in only a third. Adverse events that increased in frequency in treated patients included headache, nausea, abdominal pain, and hot flushes. Conclusions: Lenercept failed to be beneficial, but insight into the role of TNF in MS exacerbations was gained.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
The assessment and analysis of handedness: The Edinburgh inventory
Oldfield, R. C. (1971) · Neuropsychologia · doi:10.1016/0028-3932(71)90067-4 · Cited by 35,900
Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
Kurtzke, J. F. (1983) · Neurology · doi:10.1212/wnl.33.11.1444 · Cited by 15,011
Cox, D. R., & Oakes, D. (2018) · Chapman & Hall/CRC eBooks · doi:10.1201/9781315137438 · Cited by 6,234
Cox’s regression model for counting processes: A large sample study
Andersen, P. K., & Gill, R. D. (1982) · The Annals of Statistics · doi:10.1214/aos/1176345976 · Cited by 4,419
Unified Parkinson's Disease Rating Scale
(2012) · SpringerReference · doi:10.1007/springerreference_184495 · Cited by 3,066
Litvan, I., Agid, Y., Calne, D., Campbell, G., Dubois, B., Duvoisin, R. C., Goetz, C. G., Golbe, L. I., Grafman, J., Growdon, J. H., et al. (1996) · Neurology · doi:10.1212/wnl.47.1.1 · Cited by 2,538
A Modified Card Sorting Test Sensitive to Frontal Lobe Defects
Nelson, H. E. (1976) · Cortex · doi:10.1016/s0010-9452(76)80035-4 · Cited by 2,454
Recent developments in Parkinson's disease
Fahn, S., Elton, R., MARSDEN, C. D., Calne, D. B., & Goldstein, M. (1986) · Raven Press eBooks · Cited by 2,306
The IFNB Multiple Sclerosis Study Group (1993) · Neurology · doi:10.1212/wnl.43.4.655 · Cited by 2,085
Self-citationEbers, G. C. (1998) · The Lancet · doi:10.1016/s0140-6736(98)03334-0 · Cited by 2,073
Paty, D. W., Li, D. K. B., the UBC MS/MRI Study Group, & the IFNB Multiple Sclerosis Study Group (1993) · Neurology · doi:10.1212/wnl.43.4.662 · Cited by 1,967
Self-citationSTEELE, J. C. (1964) · Archives of Neurology · doi:10.1001/archneur.1964.00460160003001 · Cited by 1,924
Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro
Selmaj, K. W., & Raine, C. S. (1988) · Annals of Neurology · doi:10.1002/ana.410230405 · Cited by 1,368
Exacerbations of multiple sclerosis in patients treated with gamma interferon
Panitch, H., Haley, A., Hirsch, R., & Johnson, K. (1987) · The Lancet · doi:10.1016/s0140-6736(87)92863-7 · Cited by 1,071
Visuospatial Judgment: A Clinical Test
Benton, A. L. (1978) · Archives of Neurology · doi:10.1001/archneur.1978.00500300038006 · Cited by 1,012
The mini‐mental state examination: Normative study of an Italian random sample
Measso, G., Cavarzeran, F., Zappalà, G., Lebowitz, B. D., Crook, T. H., Pirozzolo, F. J., Amaducci, L. A., Massari, D., & Grigoletto, F. (1993) · Developmental Neuropsychology · doi:10.1080/87565649109540545 · Cited by 811
Sharief, M. K., & Hentges, R. (1991) · New England Journal of Medicine · doi:10.1056/nejm199108153250704 · Cited by 809
Tumor necrosis factor identified in multiple sclerosis brain.
Hofman, F. M., Hinton, D. R., Johnson, K., & Merrill, J. E. (1989) · The Journal of experimental medicine · doi:10.1084/jem.170.2.607 · Cited by 801
van Oosten, B. W., Barkhof, F., Truyen, L., Boringa, J. B., Bertelsmann, F. W., von Blomberg, B. M. E., Woody, J. N., Hartung, H.-P., & Polman, C. H. (1996) · Neurology · doi:10.1212/wnl.47.6.1531 · Cited by 733
Ruddle, N. H., Bergman, C. M., McGrath, K. M., Lingenheld, E. G., Grunnet, M. L., Padula, S. J., & Clark, R. B. (1990) · The Journal of experimental medicine · doi:10.1084/jem.172.4.1193 · Cited by 688
Imitating Gestures: A Quantitative Approach to Ideomotor Apraxia
De Renzi, E. (1980) · Archives of Neurology · doi:10.1001/archneur.1980.00500500036003 · Cited by 652
Corticodentatonigral Degeneration With Neuronal Achromasia
Rebeiz, J. J., Kolodny, E. H., & Richardson, E. P. (1968) · Archives of Neurology · doi:10.1001/archneur.1968.00470310034003 · Cited by 627
Two forms of ideomotor apraxia
Heilman, K. M., Rothi, L. J., & Valenstein, E. (1982) · Neurology · doi:10.1212/wnl.32.4.342 · Cited by 581
TNF is a potent anti-inflammatory cytokine in autoimmune-mediated demyelination
Liu, J., Marino, M. W., Wong, G., Grail, D., Dunn, A., Bettadapura, J., Slavin, A. J., Old, L., & Bernard, C. C. A. (1998) · Nature Medicine · doi:10.1038/nm0198-078 · Cited by 550
Selmaj, K. W., Farooq, M., Norton, W. T., Raine, C. S., & Brosnan, C. F. (1990) · The Journal of Immunology · doi:10.4049/jimmunol.144.1.129 · Cited by 544
Raven's coloured progressive matrices: normative values on 305 adult normal controls.
Basso, A., Capitani, E., & Laiacona, M. (1987) · PubMed · Cited by 480
Litvan, I., Hauw, J. J., Bartko, J. J., Lantos, P. L., Daniel, S. E., Horoupian, D. S., McKee, A., Dickson, D., Bancher, C., Tabaton, M., et al. (1996) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199601000-00010 · Cited by 475
Miller, D. H., Albert, P. S., Barkhof, F., Francis, G., Frank, J. A., Hodgkinson, S., Lublin, F. D., Paty, D. W., Reingold, S. C., & Simon, J. (1996) · Annals of Neurology · doi:10.1002/ana.410390104 · Cited by 444
Anti—tumor necrosis factor therapy abrogates autoimmune demyelination
Selmaj, K., Raine, C. S., & Cross, A. H. (1991) · Annals of Neurology · doi:10.1002/ana.410300510 · Cited by 436
Corticobasal degeneration: A clinical study of 36 cases
Rinne, J. O., Lee, M. S., Thompson, P. D., & Marsden, C. D. (1994) · Brain · doi:10.1093/brain/117.5.1183 · Cited by 408
Beck, J., Rondot, P., Catinot, L., Falcoff, E., Kirchner, H., & Wietzerbin, J. (1988) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1988.tb03663.x · Cited by 405
Accuracy of the Clinical Diagnosis of Corticobasal Degeneration: A Clinicopathologic Study
Litvan, I., Agid, Y., Goetz, C., Jankovic, J., Wenning, G. K., Brandel, J. P., Lai, E. C., Verny, M., Ray-Chaudhuri, K., McKee, A., et al. (1997) · Neurology · doi:10.1212/wnl.48.1.119 · Cited by 380
Rieckmann, P., Albrecht, M., Kitze, B., Weber, T., Tumani, H., Broocks, A., Lüer, W., Helwig, A., & Poser, S. (1995) · Annals of Neurology · doi:10.1002/ana.410370115 · Cited by 334
Cytokine levels in the cerebrospinal fluid and serum of patients with multiple sclerosis
Maimone, D., Gregory, S., Arnason, B. G. W., & Reder, A. T. (1991) · Journal of Neuroimmunology · doi:10.1016/0165-5728(91)90073-g · Cited by 333
Protection against endotoxic shock by a tumor necrosis factor receptor immunoadhesin.
Ashkenazi, A., Marsters, S. A., Capon, D. J., Chamow, S. M., Figari, I. S., Pennica, D., Goeddel, D. V., Palladino, M. A., & Smith, D. H. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.23.10535 · Cited by 275
Daniel, S. E., de Bruin, V. M. S., & Lees, A. J. (1995) · Brain · doi:10.1093/brain/118.3.759 · Cited by 274
Feany, M. B., Mattiace, L. A., & Dickson, D. W. (1996) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199601000-00006 · Cited by 264
A neurologic rating scale (NRS) for use in multiple sclerosis
Sipe, J. C., Knobler, R. L., Braheny, S. L., Rice, G. P. A., Panitch, H. S., & Oldstone, M. B. A. (1984) · Neurology · doi:10.1212/wnl.34.10.1368 · Cited by 255
Pillon, B., Blin, J., Vidailhet, M., Deweer, B., Sirigu, A., Dubois, B., & Agid, Y. (1995) · Neurology · doi:10.1212/wnl.45.8.1477 · Cited by 243
Multiple testing in clinical trials
Bauer, P. (1991) · Statistics in Medicine · doi:10.1002/sim.4780100609 · Cited by 241
Atypical presentation of progressive supranuclear palsy
Davis, P. H., Bergeron, C., & McLachlan, D. R. (1985) · Annals of Neurology · doi:10.1002/ana.410170406 · Cited by 239
Lesslauer, W., Tabuchi, H., Gentz, R., Brockhaus, M., Schlaeger, E. J., Grau, G., Piguet, P. F., Pointaire, P., Vassalli, P., & Loetscher, H. (1991) · European Journal of Immunology · doi:10.1002/eji.1830211134 · Cited by 237
Baker, D., Butler, D., Scallon, B. J., O'Neill, J. K., Turk, J. L., & Feldmann, M. (1994) · European Journal of Immunology · doi:10.1002/eji.1830240916 · Cited by 229
Cytokine mRNA levels in mononuclear blood cells from patients with multiple sclerosis
Rieckmann, P., Albrecht, M., Kitze, B., Weber, T., Tumani, H., Broocks, A., Lüer, W., & Poser, S. (1994) · Neurology · doi:10.1212/wnl.44.8.1523 · Cited by 225
Corticobasal degeneration: Neuropathologic and clinical heterogeneity
Schneider, J. A., Watts, R. L., Gearing, M., Brewer, R. P., & Mirra, S. S. (1997) · Neurology · doi:10.1212/wnl.48.4.959 · Cited by 218
The nature of apraxia in corticobasal degeneration.
Leiguarda, R. C., Lees, A. J., Merello, M., STARKSTEIN, S. E., & MARSDEN, C. D. (1994) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.57.4.455 · Cited by 172
Klinkert, W. E. F., Kojima, K., Lesslauer, W., Rinner, W., Lassmann, H., & Wekerle, H. (1997) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(96)00183-x · Cited by 143
Primary progressive aphasia with focal neuronal achromasia
Lippa, C. F., Cohen, R., Smith, T. W., & Drachman, D. A. (1991) · Neurology · doi:10.1212/wnl.41.6.882 · Cited by 131
Human tumor necrosis factor-α augments experimental allergic encephalomyelitis in rats
Kuroda, Y., & Shimamoto, Y. (1991) · Journal of Neuroimmunology · doi:10.1016/0165-5728(91)90125-q · Cited by 129
A memory test for longitudinal measurement of mild to moderate deficits.
Randt, C. T., Brown, E. R., & Osborne, D. P. (1980) · The Clinical Neuropsychologist · Cited by 126
Progressive supranuclear palsy
Gearing, M., Olson, D. A., Watts, R. L., & Mirra, S. S. (1994) · Neurology · doi:10.1212/wnl.44.6.1015 · Cited by 120
Magnetic resonance imaging in progressive supranuclear palsy and other parkinsonian disorders
Savoiardo, M., Girotti, F., Strada, L., & Ciceri, E. F. M. (1994) · Journal of neural transmission. Supplementum · doi:10.1007/978-3-7091-6641-3_8 · Cited by 119
Unusual clinical presentations of cortical‐basal ganglionic degeneration
Bergeron, C., Pollanen, M. S., Weyer, L., Black, S. E., & Lang, A. E. (1996) · Annals of Neurology · doi:10.1002/ana.410400611 · Cited by 108
The neuropathology of progressive supranuclear palsy
Lantos, P. L. (1994) · Journal of neural transmission. Supplementum · doi:10.1007/978-3-7091-6641-3_11 · Cited by 84
Massman, P. J., Kreiter, K. T., Jankovic, J. J., & Doody, R. S. (1996) · Neurology · doi:10.1212/wnl.46.3.720 · Cited by 76
Testing cognition may contribute to the diagnosis of movement disorders
Pillon, B., Dubois, B., & Agid, Y. (1996) · Neurology · doi:10.1212/wnl.46.2.329 · Cited by 75
Immune complexes are potent inhibitors of interleukin‐12 secretion by human monocytes
Berger, S., Chandra, R., Balló, H., Hildenbrand, R., & Stutte, H. J. (1997) · European Journal of Immunology · doi:10.1002/eji.1830271136 · Cited by 68
MRI in corticobasal degeneration
Grisoli, M., Fetoni, V., Savoiardo, M., Girotti, F., & Bruzzone, M. G. (1995) · European Journal of Neurology · doi:10.1111/j.1468-1331.1995.tb00172.x · Cited by 47
Frontotemporal Degeneration, Pick Disease, and Corticobasal Degeneration
Neary, D. (1997) · Archives of Neurology · doi:10.1001/archneur.1997.00550230088023 · Cited by 45
PET studies in progressive supranuclear palsy
Brooks, D. J. (1994) · Journal of neural transmission. Supplementum · doi:10.1007/978-3-7091-6641-3_10 · Cited by 29
Research works printed but not linked: 1
- Sanders O, Ran R, van Riel P, et al. Neutralization of TNF by lenercept (TNFR55-IgG, Ro 45-2081) in patients with rheumatoid arthritis treated for 3 months : results of a European phase II trial. Arthritis Rheum 1996;39 (suppl 9):242.
Cited by
Noseworthy, J. H., Lucchinetti, C., Rodriguez, M., & Weinshenker, B. G. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431307 · Cited by 2,899
Reich, D. S., Lucchinetti, C. F., & Calabresi, P. A. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1401483 · Cited by 2,491
Immunology of multiple sclerosis
Sospedra, M., & Martin, R. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115707 · Cited by 2,149
TNF-mediated inflammatory disease
Bradley, Jr. (2008) · The Journal of Pathology · doi:10.1002/path.2287 · Cited by 2,094
Compston, A., & Coles, A. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08220-x · Cited by 1,743
Metadata
- Authors
- The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group
- Venue
- Neurology
- Published
- 1999-08
- Volume
- 53
- Issue
- 3
- Pages
- 457-457
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2480036115
- Cited by
- 1,017
- References
- 62
- FWCI
- 20.56
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.